Komori
Rohto Pharmaceutical (4527) · InitiativeRestated

Clarifying business direction and optimizing the allocation of management resources

First written in FY2016. 26 of 28 entries say "Restated". Latest entry: FY2027-H1.

28entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2026-H12016: 320162017: 420172018: 320182019: 320192020: 320202021: 320212022: 220222023: 220232024: 220242025: 120252026: 22026
Same theme, other companies
Strengthening the earnings base through the selective allocation and concentration of management resourcesA theme 224 companies write about · 0 as a headwind · 233 as a tailwind

64 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.Comparing 200 of the theme's 233 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1RestatedAnnual report

    「Our group operates across a wide range of businesses in Japan and overseas, including eyecare, skincare, oral and food products, prescription ophthalmology, medical businesses such as regenerative medicine, and other related businesses, but we will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its longstanding policy of clarifying the direction of each business area and optimizing the allocation of management resources, with prescription ophthalmology and medical businesses included in the portfolio.
  2. FY2026ReframedAnnual report

    「Our basic policy is to thoroughly enforce the group's shared philosophy, values, and quality and ethical standards as a common foundation, while respecting the autonomy and independence of each region and subsidiary in formulating specific business strategies.」

    The company is repositioning its longstanding policy of optimizing the direction of each business and the allocation of management resources as a group management policy that combines globally shared principles and quality standards with autonomous business strategies for each region and subsidiary.
  3. FY2026-H1RestatedAnnual report

    「Although our Group's business portfolio spans a wide range of areas in Japan and overseas, including eye care, skincare, oral medicines, other related businesses and new businesses such as regenerative medicine, we will clarify the direction of each business and continue optimizing the allocation of management resources.」

    The company is reaffirming its longstanding policy of clarifying the direction of each business and optimizing the allocation of management resources.
  4. FY2025-H1RestatedAnnual report

    「Although our Group's business portfolio spans a wide range of areas in Japan and overseas, including eye care, skincare, oral medicines, other related businesses and new businesses such as regenerative medicine, we will clarify the direction of each business and continue optimizing the allocation of management resources.」

    The company is reaffirming its policy of clarifying the direction of each business and optimizing the allocation of management resources.
  5. FY2024-Q3RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its policy of clarifying the direction of each business and optimizing the allocation of management resources.
  6. FY2024-Q2RestatedAnnual report

    「Although our Group's business portfolio spans a wide range of areas in Japan and overseas, including eye care, skincare, oral medicines, other related businesses and new businesses such as regenerative medicine, we will clarify the direction of each business and continue optimizing the allocation of management resources.」

    The company is reaffirming its policy of clarifying the direction of each business and optimizing the allocation of management resources.
  7. FY2024-Q1RestatedAnnual report

    「Although our Group's business portfolio spans a wide range of areas in Japan and overseas, including eye care, skincare, oral medicines, other related businesses and new businesses such as regenerative medicine, we will clarify the direction of each business and continue optimizing the allocation of management resources.」

    The company is reaffirming its policy of clarifying the direction of each business and optimizing the allocation of management resources.
  8. FY2023-Q2RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its policy of clarifying the direction of each business and optimizing the allocation of management resources.
  9. FY2023-Q1RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its policy of clarifying the direction of each business and optimizing the allocation of management resources.
  10. FY2022-Q2RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its policy of continuing to clarify the direction of its existing businesses and new businesses, including regenerative medicine, and optimize the allocation of management resources.
  11. FY2022-Q1RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its policy of continuing to clarify the direction of its existing businesses and new businesses, including regenerative medicine, and optimize the allocation of management resources.
  12. FY2021-Q3RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its policy of continuing to clarify the direction of its existing businesses and new businesses, including regenerative medicine, and optimize the allocation of management resources.
  13. FY2021-Q2RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company is reaffirming its policy of continuing to clarify the direction of its existing businesses and new businesses, including regenerative medicine, and optimize the allocation of management resources.
  14. FY2021-Q1RestatedAnnual report

    「The company works each day toward becoming a company that provides solutions for every aspect of health and beauty. Although its and the group's business portfolio spans a wide range of areas, including domestic and overseas eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, it will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has reaffirmed its policy of continuing to clarify the direction of its domestic and overseas existing businesses and new businesses such as regenerative medicine, and optimizing the allocation of management resources.
  15. FY2020-Q3RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company has reaffirmed its commitment to continue clarifying the direction of its domestic and overseas existing businesses and new businesses, including regenerative medicine, and optimizing the allocation of management resources.
  16. FY2020-Q2RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company has reaffirmed its commitment to continue clarifying the direction of its domestic and overseas existing businesses and new businesses, including regenerative medicine, and optimizing the allocation of management resources.
  17. FY2020-Q1RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company has reaffirmed its commitment to continue clarifying the direction of its domestic and overseas existing businesses and new businesses, including regenerative medicine, and optimizing the allocation of management resources.
  18. FY2019-Q3RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company has reaffirmed its commitment to clarifying the direction of each existing business and new business, including regenerative medicine, and optimizing the allocation of management resources.
  19. FY2019-Q2RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company has reaffirmed its commitment to clarifying the direction of each existing business and new business, including regenerative medicine, and optimizing the allocation of management resources.
  20. FY2019-Q1RestatedAnnual report

    「Our group’s business portfolio spans a wide range of areas, including eye care, skin care, oral medicines, other related businesses and new businesses such as regenerative medicine, both in Japan and overseas. We will continue to clarify the direction of each business and optimize the allocation of management resources.」

    The company has reaffirmed its commitment to clarifying the direction of each business and optimizing the allocation of management resources across its existing domestic and overseas businesses and new businesses, including regenerative medicine.
  21. FY2018-Q3RestatedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has reaffirmed its commitment to clarifying the direction of its wide range of businesses and optimizing the allocation of management resources.
  22. FY2018-Q2RestatedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has reaffirmed its commitment to clarifying the direction of its wide range of businesses and optimizing the allocation of management resources.
  23. FY2018-Q1RestatedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has reaffirmed its commitment to clarifying the direction of its wide range of businesses and optimizing the allocation of management resources.
  24. FY2017RestatedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company continues to clarify the direction of its wide range of businesses and optimize the allocation of management resources.
  25. FY2017-Q3RestatedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has reaffirmed its longstanding policy of clarifying the direction of its wide range of businesses and optimizing the allocation of management resources.
  26. FY2017-Q2RestatedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has reaffirmed its longstanding policy of clarifying the direction of its wide range of businesses and optimizing the allocation of management resources.
  27. FY2017-Q1RestatedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has reaffirmed the same policy as in the previous fiscal year of clarifying the direction of its wide range of businesses and optimizing the allocation of management resources.
  28. FY2016First statedAnnual report

    「The company's and group's business portfolio spans a wide range of areas, including eye care, skin care, oral medicines and food, other related businesses, overseas operations and new businesses. The company will continue clarifying the direction of each business and optimizing the allocation of management resources.」

    The company has set out an initiative to clarify the direction of its wide range of businesses and optimize the allocation of management resources.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.